- Home
- / Ascendis Pharma
Ascendis Pharma
Stock Price
$139.4
2024-08-22
Market Capitalization
$7.9 B
2024-08-22
Revenue
€266.7 M
FY, 2023
Ascendis Pharma Summary
Company Summary
- Overview
- Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology. It utilizes its TransCon technologies to develop treatments for such diseases as growth hormone deficiency (GHD), hypoparathyroidism, cancer, etc.
- Type
- Public
- Status
- Active
- Founded
- 2007
- HQ
- Hellerup, DK | view all locations
- Website
- https://ascendispharma.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Flemming Steen Jensen, Executive Vice President, Product Supply and Quality
Michael Wolff Jensen, Executive Vice President, Chief Legal Officer
Sigurd Okkels, Executive Vice President, Product Development
Operating MetricsView all
Clinical Programs
4
Jun, 2023
Trademarks
32
Jun, 2023
Trademark Applications
2
Jun, 2023
LocationsView all
3 locations detected
Hellerup HQ
Denmark
Tuborg Blvd. 12
Palo Alto, CA
United States
1000 Page Mill Rd
Heidelberg, Baden-Württemberg
Germany
584 Im Neuenheimer Feld
Ascendis Pharma Financials
Summary Financials
- Revenue (Q1, 2024)
- €95.9M
- Gross profit (Q1, 2024)
- €88.3M
- Net income (Q1, 2024)
- (€131.0M)
- Cash (Q1, 2024)
- €320.2M
- EBIT (Q1, 2024)
- (€54.9M)
- Enterprise value
- $8.3B